Haemonetics Corporation (HAE)

Return on equity (ROE)

Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022 Mar 31, 2021
Net income US$ in thousands 167,679 117,558 115,401 43,375 79,469
Total stockholders’ equity US$ in thousands 820,836 959,959 817,997 749,424 731,670
ROE 20.43% 12.25% 14.11% 5.79% 10.86%

March 31, 2025 calculation

ROE = Net income ÷ Total stockholders’ equity
= $167,679K ÷ $820,836K
= 20.43%

Haemonetics Corporation's Return on Equity (ROE) has displayed fluctuations over the years as per the provided data.

- In March 2021, the ROE stood at 10.86%, indicating that for every dollar of shareholders' equity, the company generated a return of 10.86%.
- The ROE decreased to 5.79% in March 2022, suggesting a decline in the company's ability to generate profits from the shareholders' equity.
- Subsequently, there was a notable improvement as the ROE rose to 14.11% in March 2023, indicating a positive turn in the company's profitability relative to shareholders' equity.
- In March 2024, the ROE was reported at 12.25%, maintaining a relatively strong performance.
- Unfortunately, the data for March 2025 is not available ("-"), making it challenging to analyze the most recent performance.

Overall, Haemonetics Corporation's ROE has shown variability, with some years demonstrating a stronger ability to generate returns for shareholders compared to others. Further analysis of the company's financial performance and strategic decisions would provide valuable insights into the factors influencing these fluctuations.